CLINICAL TRIALS PROFILE FOR PEGASYS

All Clinical Trials for PEGASYS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00047879 ↗	Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas	Completed	National Cancer Institute (NCI)	Phase 2	2002-10-01	This study will examine the safety and effectiveness of peginterferon alpha-2b (PEG-Intron) alone and together with thalidomide in patients with gliomas (a type of brain tumor). Gliomas are nourished by blood delivered through blood vessels whose formation is stimulated by substances produced by the tumor itself. Stopping the growth of new vessels can slow or prevent tumor growth. The Food and Drug Administration has approved various interferons for treating several diseases, including melanoma and some leukemias. These drugs block new vessel growth in patients with recurrent tumors, but in high doses they produce serious side effects. Therefore, this study will use a low dose of PEG-Intron given weekly instead of high doses given several times a week. Thalidomide, currently approved to treat leprosy, also blocks development of new blood vessel formation. In a recent study of thalidomide given to 36 patients with gliomas, 4 patients had tumor shrinkage, 12 had stable disease for at least 2 months, and at least 3 had responses to treatment lasting 6 to 14 months. Patients 18 years of age and older with a primary glioma whose tumor has recurred or is growing following standard treatment and does not respond to radiation therapy may be eligible for this study. Candidates will be screened with a physical examination, blood and urine tests (including a pregnancy test for women of childbearing potential), and magnetic resonance imaging (MRI) or computed tomography (CT) of the head. Patients will continue treatment cycles as long as the drug is tolerated without serious side effects and the tumor is not growing. While on the study, patients will undergo various tests and procedures as follows: Physical and neurologic examinations every 6 weeks MRI or CT brain scan every 6 weeks to assess tumor status. MRI is a diagnostic test that uses a strong magnetic field and radio waves to show structural and chemical changes in tissues. During the scan, the patient lies on a table in a narrow cylinder containing a magnetic field. He or she can speak with a staff member through an intercom system at all times during the procedure.
NCT00048945 ↗	Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B	Completed	Hoffmann-La Roche	Phase 3	2002-01-01	The purpose of this study is to determine the safety and efficacy of Pegasys + placebo + lamivudine versus lamivudine alone in patients with lamivudine versus lamivudine alone in patients with hepatitis B antigen CHB.
NCT00056862 ↗	Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 4	2003-03-01	This study will examine the effectiveness of low-dose peginterferon and ribavirin therapy for certain patients with chronic hepatitis C-a liver disease that, in some patients, can progress to cirrhosis of the liver, liver cancer, and liver failure.
NCT00077636 ↗	ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.	Completed	Hoffmann-La Roche	Phase 4	2003-12-01	This study will evaluate the efficacy and safety of different durations of treatment with PEGASYS combined with ribavirin in patients with CHC genotype 2 or 3 infection who have never previously received interferon (IFN) therapy. The anticipated time on study treatment is 3-12 months and the target sample size is 500+ individuals.
NCT00077649 ↗	A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).	Completed	Hoffmann-La Roche	Phase 4	2004-01-01	The effects of treatment with different doses of PEGASYS in combination with different doses of ribavirin will be evaluated in patients with CHC genotype 1 who have a high viral titer, body weight greater than 85kg (187lbs) and no prior treatment with interferon. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.

Clinical Trial Conditions for PEGASYS

Condition Name

Condition Name for PEGASYS
Intervention	Trials
Hepatitis C, Chronic	87
Hepatitis C	57
Chronic Hepatitis C	35
Hepatitis B, Chronic	33

Condition MeSH

Condition MeSH for PEGASYS
Intervention	Trials
Hepatitis	280
Hepatitis A	246
Hepatitis C	212
Hepatitis, Chronic	173

Clinical Trial Locations for PEGASYS

Trials by Country

Trials by Country for PEGASYS
Location	Trials
Canada	171
Australia	95
Italy	93
Germany	91
Spain	82

Trials by US State

Trials by US State for PEGASYS
Location	Trials
California	95
Texas	89
New York	75
Florida	70
North Carolina	63

Clinical Trial Progress for PEGASYS

Clinical Trial Phase

Clinical Trial Phase for PEGASYS
Clinical Trial Phase	Trials
Phase 4	94
Phase 3	67
Phase 2/Phase 3	10

Clinical Trial Status

Clinical Trial Status for PEGASYS
Clinical Trial Phase	Trials
Completed	241
Unknown status	30
Terminated	24

Clinical Trial Sponsors for PEGASYS

Sponsor Name

Sponsor Name for PEGASYS
Sponsor	Trials
Hoffmann-La Roche	114
Bristol-Myers Squibb	22
Vertex Pharmaceuticals Incorporated	18

Sponsor Type

Sponsor Type for PEGASYS
Sponsor	Trials
Industry	259
Other	216
NIH	14

Pegasys (peginterferon alfa-2a): Clinical Trial Update, Market Analysis, and Projection

Last updated: May 4, 2026

What is Pegasys and which approvals anchor its market?

Pegasys is peginterferon alfa-2a. Its key commercial positioning comes from established use in hepatitis C virus (HCV) treatment pathways and later constrained roles as direct-acting antivirals (DAAs) took over standard of care.

Commercial anchor products

• Pegasys (peginterferon alfa-2a): long-standing branded peginterferon with legacy HCV regimens.
• Combination legacy: Pegasys was used with other agents in older interferon-era HCV regimens; DAAs displaced most interferon-based therapy in many geographies.

Regulatory status (legacy scope)

• Pegasys received approvals across major markets for chronic hepatitis C in interferon-based regimens; the dominant commercial use declined as DAAs expanded.
• The drug continues to exist in formularies and historical treatment frameworks, but active uptake depends on country-specific availability and guideline pathways.

Source trail for product identity and history

• Pegasys product monographs and licensing information are available via manufacturer and regulatory-facing drug references. (See cited sources at end.) [1–3]

---

What is the clinical trial update for Pegasys?

A clinical-trials update for Pegasys depends on whether the question targets (i) new registrational trials, (ii) line extensions, or (iii) post-approval investigator-initiated studies.

Registrational momentum

• No new, large-scale registrational phase programs for Pegasys in HCV that would typically reset market expectations are evident in the most visible public registries at this time.
• The peginterferon category has largely moved to late-stage observational, comparative effectiveness, and historical analyses, with DAAs driving the newest registrational cycles in HCV.

What has persisted in the public trial landscape Public clinical trial records for peginterferons commonly shift from:

• Efficacy for new regimens (earlier era) to
• Safety characterization, tolerability, and comparative outcomes (later era), and
• Special populations and real-world effectiveness

Implication for “update”

• From a market-planning perspective, Pegasys is best treated as a legacy asset with ongoing but limited trial productivity relative to DAA-era incumbents.

Public record basis

• Pegasys clinical trials and study listings can be tracked through major clinical registries; however, the current landscape is dominated by non-registrational follow-on work rather than new pivotal programs. [4]

---

How does Pegasys compete in HCV now?

Pegasys’ competitive position is structurally constrained by standard-of-care displacement.

Standard-of-care displacement

• DAAs achieve high sustained virologic response rates with shorter courses and better tolerability than peginterferon-based regimens.
• Pegasys’ usage depends on residual settings where interferon remains a consideration (policy, access, payer constraints, or specific clinical niches).

Therapy architecture comparison

Dimension	Pegasys (peginterferon alfa-2a)	DAA regimens
Backbone type	Immunomodulatory cytokine therapy	Direct antiviral targeting viral proteins
Treatment duration (typical modern practice)	Historically longer	Shorter courses are standard
Tolerability	Flu-like symptoms, cytopenias, psychiatric effects (class risks)	Improved tolerability profile
Outcome drivers	Peginterferon dose and immune response	Regimen potency and viral kinetics

Policy-driven competition Even when clinicians consider older options, national guideline updates and procurement pricing typically favor DAA access.

---

What is the current market structure for Pegasys?

Pegasys is no longer a growth platform; it sits in a declining category with pockets of continued demand.

Demand drivers

• Access constraints: In some markets, DAA pricing and reimbursement can limit penetration. Where DAAs are restricted, interferon-era therapy may persist at low volumes.
• Institutional legacy: Hospitals and prescribers accustomed to older pathways can keep low-level utilization going.
• Formulary inertia: Existing stock cycles and formulary decisions can prolong usage.

Demand headwinds

• Guideline shift to DAAs: Most high-income market standards have moved away from peginterferon-based therapy.
• Safety profile: Class toxicities raise monitoring burden and discourage use when DAAs are available.
• Biosimilar and generic pressures: Pegasys is a branded peginterferon; category pressure affects price flexibility.

Market consequence Pegasys pricing power depends on where it remains reimbursed and how payers structure incentives versus DAA coverage.

---

How to project Pegasys revenue trajectory: base, downside, and upside

Without new major registrational catalysts, projection must follow adoption and displacement dynamics.

Projection logic

• Base case: Continued steady attrition as DAAs expand and guideline penetration increases; modest utilization persists in constrained markets.
• Downside case: Faster displacement due to payer tightening, improved DAA access, and substitution to off-patent or lower-cost interferon alternatives.
• Upside case: Slower attrition driven by continued restrictions in access-limited geographies and continued reimbursement pockets.

Scenario framework (index-style, not absolute)

Assume 2025 as index 100 for Pegasys annual demand.

Year	Base case (index)	Downside (index)	Upside (index)
2026	88	80	92
2027	79	68	86
2028	71	58	81
2029	64	50	77
2030	58	43	73

Revenue translation Revenue tracks demand with pricing declines from competitive pressure and contracting reimbursement. Under displacement dynamics, pricing typically erodes faster than volume in late-stage legacy products.

Commercial posture recommendation (investment lens)

• Treat Pegasys as a cash-yielding, cost-controlled asset with limited upside unless a new regulatory indication emerges or a policy shift reverses DAAs’ access dominance. That scenario is outside the visible clinical and regulatory signal set.

---

What does Pegasys’ competitive landscape look like for next-stage investment?

Key competitive sets

• DAA incumbents by regimen: Multiple manufacturers compete on price, access, and guideline inclusion.
• Interferon alternatives: In any market where peginterferon is used, competition includes other peginterferon products and off-patent options where applicable.
• Supportive care and monitoring pathways: Even when DAAs are inaccessible, the economic model depends on monitoring burden and adverse event management.

Where Pegasys could still matter

Pegasys can matter when:

• DAA access is restricted by payer budgets or national procurement timing
• Specific clinical contraindications narrow DAA use (rare in practice relative to standard pathways)
• Interferon-era programs remain in place during transitional periods

This is not the same as growth. It is inventory and policy dependent.

---

Key Takeaways

• Pegasys is a legacy HCV peginterferon product whose market trajectory is dominated by DAA displacement rather than new clinical registrational progress. [1–4]
• Public clinical trial visibility indicates limited evidence of new pivotal phase programs that would materially change demand expectations. [4]
• Market demand should be modeled as continued decline with regional access pockets sustaining low-level utilization, producing a scenario path consistent with attrition through 2030.

---

FAQs

1) Is Pegasys undergoing new pivotal trials that could restart growth?
No visible registrational-scale programs are apparent in the public trial landscape at present, and the category’s development has shifted toward DAAs and observational work. [4]

2) Why does Pegasys still have market relevance?
Pegasys retains relevance in markets and reimbursement environments where DAA access is delayed or constrained, leaving residual interferon-era pathways in place. [1–3]

3) What drives Pegasys demand decline most?
Guideline changes and payer preference for DAA regimens with better tolerability and higher cure rates reduce interferon-based prescribing. [1–3]

4) What is the most likely revenue trajectory through 2030?
A continued decline across base and downside cases, with only limited upside from slower access expansion in constrained geographies. The projection framework above assumes that pattern. [1–4]

5) What would change Pegasys’ outlook materially?
A new, regulator-accepted indication with meaningful efficacy and a clinical development plan capable of generating new evidence at scale. The current public signal set does not point to that pathway. [4]

---

References (APA)

[1] FDA. (n.d.). Pegasys (peginterferon alfa-2a) information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/
[2] EMA. (n.d.). Pegasys (peginterferon alfa-2a) product information. European Medicines Agency. https://www.ema.europa.eu/
[3] Roche. (n.d.). Pegasys prescribing information and product materials. https://www.roche.com/
[4] ClinicalTrials.gov. (n.d.). Pegasys (peginterferon alfa-2a) clinical studies. https://clinicaltrials.gov/